Part D Plans’ Single Source Drug Negotiations Yielding “Significant” Savings, BIO Analysis Concludes
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare Part D drug plan sponsors are negotiating “significant” discounts for single source brand drugs, the Biotechnology Industry Organization asserts in a report issued Feb. 26.
You may also be interested in...
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.
Observational Study Quality Checklist Gets Mixed Reviews In Validation Study
The validation study finds challenges in correlating expert opinion on what is a good observational study that can be used for decision making and what the GRACE Initiative checklist predicts is a good study. Validation study author Robert Dubois believes the checklist can be predictive of a good study when the context of how an observational study’s findings are to be used is clear.